What role is #drugrepositioning to take in future drug development? Interview of Aris Persidis to Total BioPharma’s Matt Turner 5 April 2012 “I see a very significant role for drug repositioning in current and also future drug development. Not only is it driven by the patent cliff, which is not a singular event but a … Read More
Year: 2012
Biovista to host Drug Repositioning Workshop at 2nd World PGX Summit
CHARLOTTESVILLE, Virginia, March 20, 2012 — Biovista announced today that it will be organizing a workshop on drug repositioning at the upcoming World Pharmacogenomics Summit being held April 24-26 in Boston. The Workshop entitled “Understand How to Use PGx in Drug Repositioning, Adverse Event Prediction, Patient Subpopulation Stratification and Personalized Medicine” will help strategic level … Read More
Pharmaceutical Engineering interview with Dr. Aris Persidis
Industry Interview Series: Dr. Aris Persidis, President and Co-founder, Biovista, Inc. Online article in Pharmaceutical Engineering Magazine. With patent expirations looming for many major pharmaceutical companies, drug repositioning has become a matter of intense interest during the past few years. Biovista’s President and Co-founder discusses the basics of drug repositioning and the potential impact it … Read More
Biovista Awarded Research Grant on Chronic Fatigue Syndrome From Solve ME/CFS Initiative
CHARLOTTESVILLE, Virginia, March 6, 2012 /PRNewswire/ — Biovista announced today that it has been awarded a prestigious research grant by Solve ME/CFS Initiative to identify non-obvious mechanisms of the disease and potential drug repositioning candidates that will advance objective diagnosis and effective treatment of chronic fatigue syndrome (CFS). As part of its work, Biovista will share … Read More
CFIDS grant: Presentation of project members
Breaking Ground Article by K. Kimberly McCleary, about the Research Institute Without Walls. We believe in the power of systematically exploring all drugs and mechanisms for their potential against any disease. We have used this idea as the driving force to create a technologic capability, COSS, that maps and ranks all drugs versus all diseases, side … Read More